Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levamisole and Isoprinosine for COVID-19 Prophylaxis
NCT04360122Phase 3
Key facts
- Status
- Unknown
- Start
- May 2020
- Primary completion
- Nov 2020
- Countries
- 1
- Sponsor
- Ain Shams University
- Modality
- Small Molecules
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 3, randomised, open-label trial of levamisole and inosine pranobex in coronavirus disease 2019 (COVID-19), sponsored by Ain Shams University. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Healthy healthcare workers with negative COVID-19 serology, excluding those with chronic illnesses, immunodeficiencies, or taking immunosuppressants.
04
Registry description
This randomized open labeled clinical trial will include one hundred healthy healthcare workers who will be randomly assigned into four groups of twenty-five each to receive either levamisole, Isoprinosine, combined levamisole and isoprinosine or no-intervention for two months to detect the impact of Levamisole and Isoprinosine as immune-prophylaxis on the incidence of COVID-19 infection. Participants will be followed-up for three months clinically and laboratory. Blood samples will be collected prior to randomization and during follow up.
Beyond the preview
Go deeper on NCT04360122.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04360122.